Dedicated To Individual HealthPersonalized medicine and drug development in organ transplantation and immunological disorders.
PleximmuneTMPredicts the risk of acute cellular rejection after liver or intestine transplantation in children.
Cell-Based BiomarkersCombined drug-biomarker development for immunological disorders.
PlexCMVTMMeasuring cell mediated immunity to Cytomegalovirus
Plexision’s first patented product, the PleximmuneTM test, predicts the risk of acute cellular rejection after liver or intestine transplantation in children
The PleximarkTM blood test assesses the likelihood of acute cellular rejection after renal transplantation.
Plexision performs custom R and D projects aimed at integrating biomarker targets in all phases of drug development, from preclinical to post- marketing.
Immuno-Oncology is a rapidly growing area of tumor therapy that fights cancer
-
by recruiting the patient’s immune system, or
-
with drugs that are based on immune mechanisms.
PlexCMVTM is a blood test to measure the level of cellular immunity to Cytomegalovirus (CMV). Decreased anti-CMV immunity increases the risk of CMV infection.
PlexEBVTM is a lab developed blood test to measure the level of cellular immunity to Epstein-Barr virus (EBV). Decreased anti-EBV immunity increases the risk of EBV infection.
Immune deficiency can impair cellular or antibody-mediated immune responses and cause recurrent infections and cancers. Our test panel evaluates T-cell dysfunction using mitogen and antigen stimulation.
PlexCovid-19 is an investigational blood test to measure cell-mediated immunity to the SARS-CoV-2 virus.